What's new? Log in Free sign up

Filing search / Kineta, Inc. / "Access"

Search information

Kineta, Inc.

Companies

"Access"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

144 results

Newest first Best match first

KANT Kineta, Inc.

Quarterly report

stock and our ability to access capital markets; the effect of COVID-19 on the foregoing; and other risks and uncertainties, including those listed

8 Aug 24

4:00pm

KANT Kineta, Inc.

Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences

to grant TuHURA exclusive access to all of Kineta’s information and personnel necessary to conduct its complete due diligence with respect to a Potential … ) provide TuHURA and its representatives with full access to Kineta’s personnel, property and assets, and all books, records, work papers and other

KANT Kineta, Inc.

Quarterly report

stock and our ability to access capital markets; the effect of COVID-19 on the foregoing; and other risks and uncertainties, including those listed

15 May 24

4:05pm

KANT Kineta, Inc.

Definitive proxy

December 31, 2023 (the “2023 Annual Report on Form 10-K”). The Notice contains instructions on how to access those documents and to cast your vote via … and the accompanying materials scheduled to be sent to stockholders? We have elected to provide access to our proxy materials to our stockholders via

26 Apr 24

4:00pm

KANT Kineta, Inc.

common stock and our ability to access capital markets; the effect of COVID-19 on the foregoing; and other risks and uncertainties, including those … and techniques or otherwise gain access to Kineta’s trade secrets or disclose its technology. Thus, Kineta may not be able to meaningfully protect its trade

21 Mar 24

4:06pm

Prospectus supplement

pqx apdt3w6julh

Shelf registration

3 Nov 23

4:25pm

Quarterly report

3 Nov 23

4:04pm

Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

a84ytgj1yu rstk6

Prospectus supplement for primary offering

Quarterly report

11 Aug 23

4:07pm

npkn3e93qqxj aqmxrcm

Prospectus supplement

Shelf registration

1 Jun 23

4:01pm

Quarterly report

11 May 23

5:22pm

Definitive proxy

28 Apr 23

5:09pm

Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

o932s0 2sy9wh5xsnb

Prospectus supplement for primary offering

31 Mar 23

4:05pm

Kineta Completes Reverse Merger with Yumanity Therapeutics

Kineta Completes Reverse Merger with Yumanity Therapeutics

Prev
1
2
3
4
5
...
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.